ARTICLES BY RONALD A. RADER

• The “New Normal”: Changing Perceptions on Bioprocess Intensification and Continuous Bioprocessing

  3/1/2021

  Process intensification and continuous bioprocessing are concepts with inconsistent definitions. What's included often varies greatly and, in some ways, has become more about aspirational goal-setting than actual innovation adoption. Here, BioPlan Associates assesses the changing perspectives of 122 bioprocess decision-makers.

• Bioprocessing Year In Review: 11 Key Trends Accelerated By COVID-19

  12/11/2020

  Despite the morbidity, deaths, and terrible societal disruptions associated with the COVID-19 pandemic, 2020 will have created something of a positive outcome for the bioprocessing sector.

• COVID-19’s Impact On Bioprocessing: Insights From Industry Leaders

  8/5/2020

  We interviewed 26 biopharma senior executives regarding how they are handling the crisis and its long-term impact on their operations. We found the pandemic has begun to catalyze and accelerate a number of significant changes, including many preexisting trends.

• Biosimilar Pipeline Experiencing 12% Annual Growth: A Progress Update

  3/26/2020

  This article compares aspects of the biosimilar development pipeline and related market evolution since 2013, including what has and hasn’t changed.

• Biosimilars Pipeline Shows Remarkable, Sustained Growth

  3/7/2019

  The biosimilars pipeline is progressing rapidly and continues to grow, with more products and more organizations involved. This article reviews the current biosimilars development pipeline and progress. 

• Top Trends In The Biopharmaceutical Industry And Bioprocessing For 2019

  12/18/2018

  This article presents trends and findings from a survey and study of 222 responsible individuals at biopharmaceutical manufacturers and CMOs in 22 countries, as well as over 130 direct suppliers of materials, services, and equipment to this industry.

• Biosimilars Pipeline Analysis: Many Products, More Competition Coming

  7/26/2016

  Our discussion of biosimilars in this article will center on developed-market GMP biosimilars. In the European market alone, biosimilars already are a multibillion-dollar business, and one that is rapidly growing.